

54 (new). The polypeptide according to claim 48 in which differences between the polypeptide sequence and SEQ ID NO:1 are limited to conservative substitutions.

*See 4*  
55 (new). The polypeptide of any one of claims 40-54 in which the polypeptide is characterized by at least one of the following activities:

- B3  
corrid*
- a. ability to associate with mannan-binding lectin;
  - b. serine protease activity or cleavage of complement factor C2 or C4;
  - c. MASP-2 activity in an in vitro assay for MBlectin complement pathway function;
  - d. competitive inhibition of one of a.-c. above.

56 (new). The polypeptide of any one of claims 40, 46, 47 or 48 in which the polypeptide binds to MASP-2 and inhibits the C2 or C4 cleavage activity of MASP-2, or both the C2 and C4 cleavage activities of MASP-2.

#### REMARKS

The above amendments are made in order to better claim the invention. It is noted that SEQ ID NO:1 corresponds to residues 16-56 of SEQ ID NO:2.

At the time filing fees were paid, claims 1-11, 22 and 28 were pending. Claim 11 was a multiply dependent claim (on 5 and 6). The filing fee as submitted by check was \$355, which did not include the special fee for presenting MD claims. The papers included an authorization to charge any deficiency to Fish & Richardson's deposit account 06-1050 (see letter of June 4, 2001). We assume that their deposit account was so charged. However, if it was not so charged at the time the filing fees are processed, you may charge it if need be to our deposit account 02-4035, nunc pro tunc. We would appreciate a phone call to alert us.

Claims 1-11, 22 and 28 counted as 14 claims for fee calculation purposes. New claims 40-54 are SD claims (+15), new claim 55 is a 15-way MD claim (+15), and new claim 56 is a 4-way

USSN - 09/874,198

MD claim (+4). Hence, for fee calculation purposes, 48 (28 excess) total claims are presented. Claims 1, 4, 40, 46, 47 and 48 (6 claims, 3 excess) are independent.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant

By: 

Iver P. Cooper  
Reg. No. 28,005

624 Ninth Street, N.W.  
Washington, D.C. 20001  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
IPC:lms  
G:\ipc\g-i\hoib\jensenius3a\pto 3rdpreamend.wpd

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

In the claims:

Claims 4, 5, 6 AND 8-11 have been amended as follows:

4 (amended). A polypeptide [containing] comprising the sequence identified as SEQ ID NO:1.

5 (amended). [A] The polypeptide according to claim 4 with a molecular mass of about 20k.

6 (amended). [A] The polypeptide with a molecular mass of about 52K and [containing] comprising the sequence identified as SEQ ID NO:1.

8 (amended). [A] The polypeptide of claim 1, said polypeptide being capable of MASP-2 activity in an in vitro assay for MBLectin complement pathway function.

9 (amended). [A] The polypeptide according to claim 1, said polypeptide being capable of competitively inhibiting MASP-2 serine protease activity.

10 (amended). [A] The polypeptide according to claim 1 comprising a fragment of the polypeptide of SEQ ID NO:2, said polypeptide being a competitive inhibitor of complexing of MBL/MASP-2.

11 (amended). [A] The polypeptide according to claim 5 or claim 6, said polypeptide having the amino acid sequence of SEQ ID NO:2.

Claims 40-56 have been added.